Aviva’s WUXI PHARMATECH, CAYMAN INC REPSTG 8 ORD SHS WX Stock Holding History

Aviva’s Portfolio WX Stock Details WX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q4	–	Sell	-19,052	Closed	-$823K	–	847
2015 Q3	$823K	Sell	19,052 -4,787	-20%	-$202K	0.01%	759
2015 Q2	$1.01M	Sell	23,839 -3,000	-11%	-$127K	0.01%	749
2015 Q1	$1.04M	Buy	26,839 +1,165	+5%	+$44.9K	0.01%	778
2014 Q4	$864K	Hold	25,674	–	–	0.01%	793
2014 Q3	$899K	Sell	25,674 -4,195	-14%	-$144K	0.01%	797
2014 Q2	$981K	Sell	29,869 -610	-2%	-$20.9K	0.01%	785
2014 Q1	$1.12M	Buy	30,479 +4,279	+16%	+$157K	0.01%	762
2013 Q4	$1.01M	Buy	+26,200	New	+$827K	0.01%	758

Other funds holding WX

Ninety One (UK) London, United Kingdom $44.7B AUM 17.24% 1-Year Est. Return

CCS

Crosspoint Capital Strategies Orinda, California $50.4M AUM 15.37% 1-Year Est. Return

Aviva's WX Position: Q4 2015 in Review

Aviva sold out of WUXI PHARMATECH, CAYMAN INC REPSTG 8 ORD SHS (WX) in Q4 2015, closing a stake of 19,052 shares — an estimated $823K sold.

Aviva first reported a position in WX in Q4 2013 and held it in 8 quarters. The position peaked at $1.12M in Q1 2014. 2 funds tracked by Wall St. Rank hold WX as of Q4 2015.

Aviva reported no remaining WUXI PHARMATECH, CAYMAN INC REPSTG 8 ORD SHS position as of Q4 2015 after selling out during the quarter.
Aviva sold 19,052 WUXI PHARMATECH, CAYMAN INC REPSTG 8 ORD SHS shares in Q4 2015, an estimated $823K.
Aviva first reported a position in WUXI PHARMATECH, CAYMAN INC REPSTG 8 ORD SHS in Q4 2013 and held it in 8 quarters.
Aviva's WUXI PHARMATECH, CAYMAN INC REPSTG 8 ORD SHS position peaked at $1.12M in Q1 2014.
2 funds tracked by Wall St. Rank held WUXI PHARMATECH, CAYMAN INC REPSTG 8 ORD SHS as of Q4 2015.

Based on Aviva's 13F filing for Q4 2015, filed 11 Feb 2016.